{"name":"Gelb, Arthur F., M.D.","slug":"gelb-arthur-f-m-d","ticker":"","exchange":"","domain":"","description":"Arthur F. Gelb, M.D. is a pharmaceutical company focused on respiratory treatments, with a portfolio of marketed drugs for asthma management. The company's key products include budesonide/formoterol and fluticasone/salmeterol combinations, which are widely used in the treatment of asthma.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"fluticasone/salmeterol in all asthmatics","genericName":"fluticasone/salmeterol in all asthmatics","slug":"fluticasone-salmeterol-in-all-asthmatics","indication":"Asthma maintenance therapy in patients ≥4 years of age","status":"marketed"}]}],"pipeline":[{"name":"fluticasone/salmeterol in all asthmatics","genericName":"fluticasone/salmeterol in all asthmatics","slug":"fluticasone-salmeterol-in-all-asthmatics","phase":"marketed","mechanism":"Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing in asthma.","indications":["Asthma maintenance therapy in patients ≥4 years of age","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}